EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

Background: Approximately 10% of patients with non-small cell lung cancer (NSCLC) harbor uncommon epidermal growth factor receptor (EGFR) alterations. This study aims to investigate the therapeutic responses and predict the binding activity of different tyrosine kinase inhibitors (TKIs) for EGFR unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Yang, Guangjian, Liu, Runze, Yang, Yaning, Li, Weihua, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523264/
https://www.ncbi.nlm.nih.gov/pubmed/36188595
http://dx.doi.org/10.3389/fphar.2022.976731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523264/
https://www.ncbi.nlm.nih.gov/pubmed/36188595
http://dx.doi.org/10.3389/fphar.2022.976731

Ejemplares similares